ClinicalTrials.gg
CompletedNCT05983770Updated Jul 22, 2026

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

A Phase 2 interventional study of AT-1501 and Tacrolimus in Kidney Transplant Rejection, sponsored by Eledon Pharmaceuticals. Completed at 43 sites in 7 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Eledon Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
185th of 638
127 · median 48
Started
2023
with 29 others
Phase 2
87 of 765
4 open now
Registered
702nd of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 185th largest by enrollment of the 638 interventional ones that give a count, is one of 30 that started in 2023, is one of 87 in phase 2, and was the 702nd registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.

Read the detailed description

This study is a randomized, multicenter, open-label, active control study to evaluate the safety and efficacy of AT-1501 compared with tacrolimus in the prevention of rejection in patients undergoing kidney transplantation. Up to 120 de novo kidney transplant recipients will receive rATG induction with corticosteroids (CS), and mycophenolate as maintenance therapy, and will be randomized 1:1 to receive either AT-1501 or tacrolimus.

03

Conditions studied

  • Kidney Transplant Rejection

Keywords

  • AT-1501
  • Kidney Transplant
  • Renal Allograft Rejection
  • Prophylaxis
  • CD40L Inhibitor
  • Humanized blocking antibody to CD40L
  • Monoclonal Antibody
  • Renal
  • Transplant
  • ESRD
  • Tegoprubart
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 years of age
  • Recipient of their first kidney transplant from a living or deceased donor
  • Agree to comply with requirements during and for at least 90 days after the last administration of study drug

Exclusion criteria

Exclusion Criteria:

  • Induction therapy, other than study assigned rATG, planned as part of initial regimen
  • Currently treated with any systemic immunosuppressive regimen, including immunologic biologic therapies
  • Currently treated with other than topical or inhaled corticosteroids
  • Will receive a kidney with an anticipated cold ischemia time of > 30 hours
  • Will receive a kidney from a donor that meets any of the following:

    • 5a. Donation after Cardiac Death (DCD) criteria; Or
    • 5b. Kidney Donor Profile Index (KDPI) of > 85%; Or
    • 5c. Is blood group (ABO) incompatible
  • Medical conditions that require chronic use of systemic corticosteroids or other immunosuppressants
  • History of a thromboembolic event, known hypercoagulable state, or condition requiring long term anticoagulation
  • Positive T- or B-cell crossmatch that is due to HLA antibodies or presence of a DSA at Screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Investigative

    AT-1501 monoclonal antibody targeting CD40L given as an IV infusion

    Drug: AT-1501

  • Active comparator
    Comparator

    Tacrolimus administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter

    Drug: Tacrolimus

Interventions

  • IV infusions of AT-1501 20 mg/kg over 1 hour.

    Also known as: Tegoprubart

  • Tacrolimus will be administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter.

06

What researchers measure

Primary outcomes

  1. eGFR at 12 months

    Estimated Glomerular Filtration Rate (eGFR) at 12 months post-transplant

    Time frame: Assessed from date of transplant through Day 364 (Month 12)

Secondary outcomes

  1. NODAT at 12 months post-transplant

    The proportion of new onset diabetes after transplant (NODAT) at 12 months post-transplant

    Time frame: Assessed from date of transplant through Day 364 (Month 12

  2. The proportion of patient and graft survival at 12 months post-transplant

    Patient and graft survival are defined as either A) Death, B) re-transplantation or C) Requirement for regular dialysis

    Time frame: Assessed from date of transplant through Day 364 (Month 12)

  3. BPAR-free patient and graft survival at 12 months post-transplant

    Assessed from date of transplant through Day 364 (Month 12)

    Time frame: The proportion of BPAR-free patient and graft survival at 12 months post-transplant

  4. BPAR at 12 months

    The proportion of BPAR at 12 months

    Time frame: Assessed from date of transplant through Day 364 (Month 12)

07

Study locations

43 sites
  • University of California Los Angeles
    Los Angeles, California 90024, United States
  • Keck School of Medicine of USC
    Los Angeles, California 90033, United States
  • University of California, Irvine Medical Center
    Orange, California 92868, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • Medstar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospita;
    Boston, Massachusetts 02114, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • University of Minnesota Medical Center
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55907, United States
  • Washington University in St. Louis
    St Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • New York University Langone Health - Tisch Hospital
    New York, New York 10016, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • University of Pittsburgh Medical Center
    Harrisburg, Pennsylvania 17104, United States
  • UT Southwestern
    Dallas, Texas 75235, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • University of Wisconsin Health
    Madison, Wisconsin 53792, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Fiona Stanley Hospital
    Perth, Western Australia 6150, Australia
  • Fundação Oswaldo Ramos - Hospital do Rim
    São Paulo, Brazil
  • Hospital das Clínicas da Faculdade de Medicina de São Paulo
    São Paulo, Brazil
  • St. Paul's Hospital
    Vancouver, British Columbia, Canada
  • Groupe Hospitalier Pellegrin
    Bordeaux, France
  • CHU Grenoble-Alpes - Hopital Nord Michallon
    Grenoble, France
  • Centre Hospitalier Universitaire Dupuytren
    Limoges, 87042, France
  • CHU de Toulouse - Hopital de Rangueil
    Toulouse, France
  • CHRU Tours - Hopital Bretonneau
    Tours, France
  • Charite Universitatsmedizin Berlin
    Berlin, Germany
  • Hospital del Mar - Parc de Salut Mar
    Barcelona, 08003, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Germans Trias i Pujol
    Barcelona, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Sep 2025, 24 months.

Of 26 industry-sponsored phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 24 months is close to that.

Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2023
First posted
Aug 9, 2023
StartActual
Aug 30, 2023
Primary completionActual
Sep 11, 2025
CompletionActual
Sep 25, 2025
Results delay requested
Jul 20, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05983770
Lead sponsor
Eledon Pharmaceuticals
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
Aug 30, 2023
Primary completion
Sep 11, 2025
Completion
Sep 25, 2025
Last update
Jul 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprubart

Start the discussion